We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) said Wednesday the U.S. Food and Drug Administration has granted priority review of the drug company's application for approval of its blood cancer treatment acalabrutinib.
AstraZeneca made a new drug application for the treatment after a Phase II trial.
The FDA grants priority review, which accelerates the assessment of drugs, to applications for medicines that, if approved, would offer a significant improvement in the treatment, diagnosis, or prevention of serious conditions.
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
August 02, 2017 02:42 ET (06:42 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
